Key clinical point: An autologous fecal transplant can restore intestinal microbiota after allogeneic hematopoietic stem cell transplant.
Major finding: All patients who received auto-FMT regained pre–allo-HSCT microbiota composition and diversity (P less than .0001).
Study details: An open-label study involving 25 allo-HSCT patients that compared auto-FMT with no treatment.
Disclosures: Study funding was provided by the Leonard Tow Foundation and the Memorial Sloan Kettering’s Center for Microbes, Inflammation, and Cancer. The authors reported disclosures related Merck, AbbVie, Nektar Therapeutics, Novartis, and others.
Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489.
This Week's Must Reads
Imaging Overuse in Low-Risk Prostate Ca Patients, Urol Oncol; 2019 Feb; Drangsholt, Walter, et al
Racial Disparities in Prostate Ca Treatment, Cancer; ePub 2019 Jan 29; Gordon, Basak, et al
Physical Activity & Prostate Cancer Progression, Cancer Epidemiol Biomarkers Prev; 2019 Feb; Dai, et al
Aspirin Use and Prostate Cancer Mortality, Cancer Epidemiol Biomarkers Prev; ePub 2018 Nov 28; Hurwitz, et al
Active Surveillance in Newly Diagnosed Prostate Ca, J Urol; ePub 2019 Jan 31; Botejue, Abbott, et al